Company: PTHS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001753926-25-001764
Chunk: 8

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 8
---
 — 

    Proceeds from loan payable, net of debt discount 
     693  
     690 

    Payment of loan payable, net of debt discount 
     (845) 
     (215)

    Common stock issued for cash 
     —  
     5,972 

    Rescission of common stock 
     —  
     (166)

    Net cash provided by financing activities 
     27,317  
     6,281 

    Net increase in cash and cash equivalents 
     13,740  
     1,159 

    Cash, cash equivalents and restricted cash as of beginning of period 
     513  
     96 

    Cash, cash equivalents and restricted cash as of end of period 
    $14,253  
    $1,255 

The
accompanying notes are an integral part of these condensed consolidated financial statements.

6

PELTHOS
THERAPEUTICS INC.  

CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS 

FOR
THE NINE MONTHS
ENDED SEPTEMBER 30, 2025 AND 2024 (CONTINUED) 

(Unaudited) 

(in
thousands, except share and per share amounts)

    Reconciliation to condensed consolidated balance sheets: 

    Cash and cash equivalents 
    $14,203  
    $513 

    Restricted cash 
     50  
     — 

    Total cash, cash equivalents and restricted cash shown in the statement of cash flows 
    $14,253  
    $513 

    Supplemental cash flow information: 

    Cash paid for income taxes 
    $
    —  
    $
    — 

    Cash paid for interest expense 
    $19  
    $— 

    Supplemental non-cash investing and financing activities: 

    PIPE proceeds allocated to accounts payable 
    $1,776  
    $— 

    PIPE proceeds allocated to debt payable 
    $20,340  
    $— 

    PIPE proceeds allocated to fees 
    $600  
    $— 

    Royalty agreement liability reclassified from additional paid in capital 
    $10,821  
    $— 

    Debt discount from common stock issued for extension of bridge loan 
    $—  
    $448